Related Experiment Videos
Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?
M Ligueros1, R Unwin, M Wilkins
1Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Insights
Blood pressure reduction alone is insufficient for treating essential hypertension. New alpha-1 blockers offer benefits for blood glucose and lipid levels, improving cardiovascular outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Essential hypertension treatment requires more than blood pressure reduction to significantly decrease ischemic heart disease morbidity and mortality.
- A multifactorial approach to cardiovascular disease prevention highlights the importance of interactions between antihypertensive therapy and metabolic factors like glucose and lipid control.
- Sympathetic nervous system dysfunction may play a role in both hypertension development and associated metabolic disturbances.
Purpose of the Study:
- To discuss the role of new generation selective alpha-1-adrenoreceptor blockers in hypertension management.
- To evaluate the impact of these blockers on lipid and glucose metabolism.
- To determine the place of selective alpha-1-adrenoreceptor blockers in the overall treatment strategy for hypertension.
Main Methods:
- Review of current literature on antihypertensive therapies and their metabolic effects.
- Analysis of studies investigating selective alpha-1-adrenoreceptor blockers.
- Discussion of clinical implications for hypertension and cardiovascular disease management.
Main Results:
- Selective alpha-1-adrenoreceptor blockers effectively lower blood pressure.
- These agents demonstrate favorable effects on lipid profiles and glucose metabolism.
- The findings suggest a potential benefit beyond simple blood pressure reduction.
Conclusions:
- Selective alpha-1-adrenoreceptor blockers represent a promising therapeutic option for essential hypertension.
- Their beneficial effects on metabolic factors warrant consideration in a multifactorial approach to cardiovascular disease prevention.
- Further research is needed to fully elucidate their long-term impact on cardiovascular outcomes.
Abstract:
It has become apparent in recent years that in the treatment of essential hypertension, reduction of blood pressure alone is not sufficient to reduce significantly the morbidity and mortality from ischaemic heart disease. Since the emergence of a multifactorial approach to the prevention of cardiovascular disease, the potential interaction between antihypertensive therapy and metabolic factors, such as control of blood glucose and lipid levels, has become an important consideration. Abnormal function of the sympathetic nervous system may contribute to both the initiation, or maintenance, of hypertension and the associated metabolic disturbances. The new generation of selective alpha 1-adrenoreceptor blockers, besides lowering blood pressure, appear to have favourable effects on lipid and glucose metabolism. The use of these drugs and their place in the treatment of hypertension are discussed.